
AcouSort strengthens its R&D capabilities by the recruitment of Henrik Johansson

AcouSort has recruited Henrik Johansson to the position as Director of Research and Technology. Henrik has significant experience from startup environment within the biotech space as well as from R&D management roles at Agilent and PerkinElmer. Going forward, he will play a key role in the further development of AcouSort's technology portfolio.

As Director of Research and Technology, Henrik will be responsible for AcouSort's Research projects. Primary focus will be on managing research activities aimed at further developing and applying AcouSort's core technology to address unmet needs identified in clinical research and practice. Henrik will also be responsible for identifying new technology frontiers that enables development of state-of-the-art products.

Henrik has extensive knowledge of developing novel products based on proprietary technology and experience of leading product development projects from idea stage to product launch.

"AcouSort is in a very important phase in the company's development. Our technology has the potential to facilitate significant advances within diagnostics and cell therapy. Henrik's knowledge and experience fit perfectly into our organization as we continue to develop and broaden our offering. I am delighted to have him onboard," says AcouSort's CEO Torsten Freltoft.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.